BioTech IP Review

Compositions and Methods for Improving Base Editing

Assignee: Beam Therapeutics Inc. (Cambridge, MA, USA)
Patent Number: 12,454,694 B2
Filing Date: September 7, 2019
Patent Issued: October 28, 2025
Inventors: John Evans & Jason Michael Gehrke

What It Covers

This patent claims base editing systems and associated compositions that enhance the efficiency, precision, and usability of base editors — a next-generation gene editing modality that Beam specializes in. The invention focuses on structural components of base editing systems (such as engineered programmable DNA binding domains combined with base-editing enzymatic domains) and the methods in which these systems can be used to conduct precise genetic modifications.

Editable Base Editor System:
A base editing apparatus comprising multiple programmable DNA binding domains (one lacking nuclease activity, the other with “nickase” activity) coupled to an adenosine deaminase domain — the enzyme responsible for executing single-base changes in DNA without creating double-strand breaks.
Guide RNA-Directed Targeting:
The system includes separate guide RNAs that direct each domain to specific DNA sequences, enabling highly targeted base substitutions in genomic DNA.
Improving Editing Outcomes:
The claimed compositions and configurations aim to improve overall base editing performance — including editing efficiency and fidelity — which is critically important for therapeutic applications like in vivo correction of disease-causing mutations.

Why It’s Important

1. Core to Beam’s Platform Technology

Base editing is the foundational gene-editing modality that differentiates Beam from standard CRISPR-Cas9 approaches — enabling precise single nucleotide changes without cutting both DNA strands. This patent strengthens Beam’s claim to improvements in base editor design, beyond just applications.

2. Supports Multiple Therapeutic Programs

This technology underlies lead clinical and preclinical programs such as BEAM-302 (for alpha-1 antitrypsin deficiency) and BEAM-101 (for sickle cell disease) — both based on in vivo or ex vivo base editing strategies that rely on high-performance base editing systems.

3. Broad Platform Protection

Rather than being limited to one particular target gene or disease, this patent covers core engineering improvements to base editors (protein components, guide RNA pairing, etc.), which can be deployed across many targets — boosting Beam’s intellectual property moat in a competitive gene editing landscape.

4. Commercial and Strategic Leverage

Owning robust foundational patents on improved base editors enhances Beam’s ability to negotiate partnerships, collaborations, and licensing deals with larger biopharma companies. It also helps with blocking competitors from using similar advanced base editing configurations.

Summary

U.S. Patent No. 12,454,694 B2, issued on October 28, 2025, protects compositions and methods that improve base editing systems — a cornerstone technology behind Beam Therapeutics’ precision gene editing platform. Because base editing is central to Beam’s clinical pipeline and future therapeutic products (e.g., treatments targeting AATD, sickle cell disease, and other genetic disorders), this patent is one of the most important and potentially lucrative pieces of intellectual property for the company.